Dr. Sinn's research focuses on developing integrating vector systems for the treatment of CF lung disease. They engineer gene delivery and gene editing tools for CF treatment, including lentiviral, adenoviral, and adeno-associated virus-based viral vectors. His research is at the forefront of developing piggyBac hybrid vector systems that integrates into airway epithelial cells, and the engineering of transposases and zinc-fingers to integrate transgenes into safe-harbor genomic loci. These systems, in addition to novel lentiviral pseudotypes developed by Dr. Sinn, are being used for lung-directed gene therapy in the CF pig and ferret models. As Director of the Viral Vector Core, he serves investigators world-wide and produce viral vectors for studies in the lung, eye, brain, liver, heart, muscle, cardiovascular, and neuromuscular systems.